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Abstract
Background: Dependences on addictive substances are substantially-heritable complex disorders
whose molecular genetic bases have been partially elucidated by studies that have largely focused
on research volunteers, including those recruited in Baltimore. Maryland. Subjects recruited from
the Baltimore site of the Epidemiological Catchment Area (ECA) study provide a potentially-useful
comparison group for possible confounding features that might arise from selecting research
volunteer samples of substance dependent and control individuals. We now report novel SNP
(single nucleotide polymorphism) genome wide association (GWA) results for vulnerability to
substance dependence in ECA participants, who were initially ascertained as members of a
probability sample from Baltimore, and compare the results to those from ethnically-matched
Baltimore research volunteers.
Results:  We identify substantial overlap between the home address zip codes reported by
members of these two samples. We find overlapping clusters of SNPs whose allele frequencies
differ with nominal significance between substance dependent vs  control individuals in both
samples. These overlapping clusters of nominally-positive SNPs identify 172 genes in ways that are
never found by chance in Monte Carlo simulation studies. Comparison with data from human
expressed sequence tags suggests that these genes are expressed in brain, especially in
hippocampus and amygdala, to extents that are greater than chance.
Conclusion: The convergent results from these probability sample and research volunteer sample
datasets support prior genome wide association results. They fail to support the idea that large
portions of the molecular genetic results for vulnerability to substance dependence derive from
factors that are limited to research volunteers.
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Background
Vulnerability to substance dependence is a complex trait
with strong genetic influences that are well documented
by data from family, adoption and twin studies [1-4].
Twin studies support the view that much of the heritable
influence on vulnerability to dependence on addictive
substances from different pharmacological classes (eg nic-
otine and stimulants) is shared [2,3,5]. Combined data
from linkage and genome wide association (GWA) data-
sets [6-11] suggest that most of the genetics of vulnerabil-
ity to dependence on addictive substances is likely to be
polygenic, arising from variants in genes whose influences
on vulnerability, taken one at a time, are relatively mod-
est. Substance-dependent individuals also differ from
control individuals in personality, cognitive domains and
co-occurrence of psychiatric diagnoses [1,12] (reviewed in
[13]).
GWA approaches of increasing sophistication have been
developed and used to identify the specific genes and
genomic variants that predispose to vulnerability to sub-
stance dependence. For example, we have assembled a
group of research volunteers from the Molecular Neurobi-
ology Branch of the NIH (NIDA) intramural research pro-
gram in Baltimore between 1990 and 2008 ("MNB"). We
have compared allele frequencies at ca  1500, 10,000,
100,000, 500,000 and then 1,000,000 SNP markers in
increasing numbers of substance dependent vs  control
individuals from this growing sample, including 680 sub-
stance dependent or control individuals with self reported
European ancestries [6-9,11], (Drgon et al, submitted).
There is the theoretical concern that this MNB sample,
and many of the other samples collected for studies of
genetics of dependence on addictive substances, might be
biased based on the requirement that subjects were ascer-
tained when they volunteered for research. It is conceiva-
ble that "volunteering" might interact with heritable
features of personality, cognitive, psychiatric and/or other
features by which substance dependent individuals might
differ from controls [1,12-25]. GWA findings in such
research volunteer samples would then conceivably pro-
vide a distorted representation of findings that would oth-
erwise be made in members of the community.
The Baltimore site of the Epidemiological Catchment Area
(ECA) Study provides a good comparison group to probe
such potential confounding features [24,26]. This study
initially assembled a probability sample of individuals
who represented the East Baltimore population, including
many of the census tracts in which MNB research volun-
teers reported their home residences. ECA investigators
followed substantial portions of these individuals, inter-
viewing them four times and sampling DNA from most of
the 1071 individuals from the initial sample who were
interviewed in 2004–05 (see below). The repeated assess-
ment of these individuals provides confident assessment
of dependence-related phenotypes that include DSM
diagnoses of substance abuse and dependence and Fager-
strom Test for Nicotine Dependence (FTND) diagnoses of
nicotine dependence.
We thus now report data that confirms the overlapping
areas of Baltimore from which ECA and MNB subjects
were sampled. We report genome wide association studies
for substance dependence phenotypes for Baltimore ECA
subjects. We compare these genome wide association
results with those from ethnically-matched MNB research
volunteers who were recruited from many of the same
areas. We discuss the significance of the substantially-
overlapping data that we report, as well as the limitations
of the samples and datasets. These data document large
molecular genetic overlaps between probability-sample




Subjects from the Baltimore (Eastern Baltimore Mental
Health Survey) site for the Epidemiological Catchment
Area Program (ECA) were ascertained as a probability
sample of individuals in dwelling units within census
tracts near the Johns Hopkins Medical Institutions and
initially interviewed in 1981 [24,26]. Subsets of these
individuals were interviewed in 1982, 1993–96 and
2004–5. Diagnoses came from the Diagnostic Interview
Schedule (DIS), a self-report instrument [27] whose valid-
ity and reliability has been documented in this sample
[27a]. Smoking was also described using the Fagerstrom
Test for Nicotine Dependence (FTND) [28-30]. Although
many of the individuals who were > 65 in 1981 had died
by the 2004–05 follow-up, self-report survey data was col-
lected from 662 European-American respondents (63%
female) during this follow-up. This subset provided good
representation of the composition of the portion of the
original Baltimore ECA cohort that was of this race/eth-
nicity. Blood for DNA extraction and for lymphocyte
immortalization was obtained from 74% of these individ-
uals, who did not differ from subjects from whom DNA
was not obtained in any obvious feature that related to
substance dependence [30a].
Individuals who were dependent on an abused substance
were identified by DSM criteria, except for nicotine
dependence which was based on FTND criteria. Eighty
substance dependent individuals were identified. These
individuals were matched for gender and age to eighty
control individuals. These control individuals were East
Baltimore ECA participants who never used any illegal
drugs more then 5 times in their lives, were not dependentBMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
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on any drug or alcohol, drank less than one drink per day
(waves 3 and 4) drank less than 5 drinks/week (waves 1
and 2) and had FTND scores < 7. Generation and analyses
of these data were approved by the Johns Hopkins
Bloomberg School of Public Health IRB and exempt pro-
tocols for pooled genotyping approved by the NIH Office
of Human Research Subject Protection.
Comparison research volunteer sample
Data from these European-American ECA subjects was
compared to data from European-American MNB
research volunteers who provided informed consents, eth-
nicity data, drug use histories and DSMIII-R or IV diag-
noses as previously described [6,31,32]. DNA in 34 pools
sampled 400 "abusers" with heavy lifetime use of illegal
substances and, for virtually all, DSMIII-R/IV dependence
on at least one illegal abused substance and 280 "con-
trols" who reported no significant lifetime use of any
addictive substance. Generation and analyses of these
data were approved by the NIH IRP (NIDA) IRB (protocol
#148) and exempt protocols for pooled genotyping
approved by the NIH Office of Human Research Subject
Protection.
DNA preparation and assessment of allelic frequencies
DNA was prepared from blood (MNB and some ECA sub-
jects) or cell lines (most ECA subjects) [6,31,32] and care-
fully quantitated. DNAs from groups of 20 individuals of
the same phenotype were combined. Hybridization
probes were prepared with precautions to avoid contami-
nation, as described (Affymetrix assays 500 k
[9,11,33,34]). 150 ng of pooled DNA was digested using
StyI or NspI, ligated to appropriate adaptors and amplified
using a GeneAmp PCR System 9700 (Applied Biosystems,
Foster City, CA) with 3 min 94°C, 30 cycles of 30 sec
94°C, 45 sec 60°C, 15 sec at 68°C and a final 7 min 68°C
extension. PCR products were purified (MinEluteTM 96
UF kits, Qiagen, Valencia, CA) and quantitated. Forty μg
of PCR product was digested for 35 min at 37°C with 0.04
unit/μl DNase I to produce 30–100 bp fragments which
were end-labeled using terminal deoxynucleotidyl trans-
ferase and biotinylated dideoxynucleotides and hybrid-
ized to the appropriate 500 k array (Sty I or Nsp I arrays)
(Mendel array sets, Affymetrix). Arrays were stained and
washed as described (Affymetrix Genechip Mapping Assay
Manual) using immunopure strepavidin (Pierce, Milwau-
kee, WI), biotinylated antistreptavidin antibody (Vector
Labs, Burlingame, CA) and R-phycoerythrin strepavidin
(Molecular Probes, Eugene, OR). Arrays were scanned and
fluorescence intensities quantitated using an Affymetrix
array scanner as described [9,11,33,34].
Chromosomal positions for each SNP were sought using
NCBI (Build 36.1) and NETAFFYX (Affymetrix) data.
Allele frequencies for each SNP in each DNA pool were
assessed based on hybridization intensity signals from
four arrays, allowing assessment of hybridization to the
12 "perfect match" cells on each array that are comple-
mentary to the PCR products from alleles "A" and "B" for
each diallelic SNP on sense and antisense strands. We
eliminated: i) SNPs on sex chromosomes and iii) SNPs
whose chromosomal positions could not be adequately
determined.
Each array was analyzed as described [9,11,33,34], with
background values subtracted, normalization to the high-
est values noted on the array, averaging of the hybridiza-
tion intensities from the array cells that corresponded to
the perfect match "A" and "B" cells, calculation of "A/B
ratios" by dividing average normalized A values by aver-
age normalized B values, arctangent transformations to
aid combination of data from arrays hybridized and
scanned on different days, and determination of the aver-
age arctangent value for each SNP from the 4 replicate
arrays. A "t" statistic for the differences between abusers
and controls was generated as described [9,11,33,34] for
each SNP. We focused on SNPs that displayed t statistics
with p < 0.05 for abuser/control differences. We sought
evidence for clustering of these SNPs by focusing on chro-
mosomal regions in which at least three of these outlier
SNPs, assessed by at least two array types, lay within 25 Kb
of each other. We term these clustered, nominally-positive
SNPs "clustered positive SNPs", and focus our analyses on
regions in which they lie.
To confirm the SNPs within the positive clusters from the
current dataset, we sought convergence between data from
these clustered nominally-positive SNPs and clustered
nominally-positive SNPs, determined in the same way,
from 1 M SNP genome wide association studies of the
MNB samples (Drgon et al, submitted). To provide
insights into some of the genes likely to harbor variants
that contribute to individual differences in vulnerability
to substance dependence, we sought candidate genes that
were identified by overlapping clusters of positive SNPs
from each of these samples.
We compare observed results to those expected by chance
using Monte Carlo simulation trials, as described
[9,11,33,34]. For each trial, a randomly-selected set of
SNPs from the current dataset was assessed to see if it pro-
vided results equal to or greater than the results that we
actually observed. The number of trials for which the ran-
domly-selected SNPs displayed (at least) the same features
displayed by the observed results was then tallied to gen-
erate an empirical p value. These simulations thus correct
for the number of repeated comparisons made in these
analyses, an important consideration in evaluating these
GWA datasets. We thus focus on genes which display con-
vergence between nominally-significant results obtainedBMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
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from the two dependence vs control samples. We report
Monte Carlo probabilities for the observed convergence of
clustered nominally positive SNPs within each gene, using
simulations that correct for the number of repeated com-
parisons.
To assess the power of our current approach, we use cur-
rent sample sizes and standard deviations, the program PS
v2.1.31 [35,36] and α = 0.05. To provide controls for the
possibilities that abuser-control differences observed
herein were due to a) occult ethnic/racial allele frequency
differences or b) noisy assays, we assessed the overlap
between the results obtained here and the SNPs that dis-
played the largest a) allele frequency differences between
African-American vs European-American control individ-
uals and b) the largest assay "noise".
We have compared the patterns of human brain expres-
sion for the genes identified herein to those identified
using a novel tool based on the distribution of expressed
sequence tags (ESTs) contained in an annotated set of
brain cDNA libraries (CYL, GRU et al, in preparation).
Briefly, we identified 846 human cDNA libraries with
cDNAs represented in dbEST. These libraries were con-
structed from regions of brains that appeared to display
modest or no pathology. We based the analyses on two
sets of criteria: 1) all entries in these libraries and 2) "more
reliable" entries that display i) correct genomic orienta-
tion and either ii a) evidence for polyA tail or ii b) spliced
structure (CYL, GRU et al, in preparation). For each brain
region, we assessed the p-value for over-representation of
expression of the dependence-associated genes using
hypergeometric distribution tests with false discovery rate
(FDR) corrections. Q-values < 0.05 were considered statis-
tically significant.
Results
We assessed the extent to which the ECA and NIDA
research volunteers came from similar Baltimore neigh-
borhoods by comparing the distributions of available zip
codes from these samples. As noted in Figure 1, there was
substantial overlap between these zip code distributions,
providing impetus for the comparative molecular genetic
studies described below.
We then assessed allele frequencies in multiple pools of
DNA from substance dependent and control ECA individ-
uals. There was modest variability among replicate arrays
that assessed the same pool (standard error of the mean
(SEM) 0.032) and among the different pools that assessed
the same phenotype (SEM 0.033). These samples and
these estimates of variance thus provided 0.9, 0.74, 0.46
and 0.21 power to detect allele frequency differences of
12.5, 10, 7.5 and 5%, respectively.
28,137 SNPs displayed "nominally positive" t values with
p < 0.05 in these ECA samples. 7,620 of these nominally
positive SNPs fell into 1660 clusters of at least 3 SNPs that
came from both array types were separated from adjacent
nominally-positive SNPs by less than 25,000 basepairs.
Monte Carlo simulations reveal p < 0.00001 for this
degree of clustering.
One hundred seventy two genes are identified by both 1)
clusters of nominally-positive SNPs from the ECA samples
and 2) overlapping clusters of nominally positive SNPs
from MNB samples. We list the 126 of these genes whose
nominal Monte Carlo p values are < 0.05 in Table 1. This
number of genes is never identified by chance in both
samples by any of 10,000 Monte Carlo simulation trials
(thus, p < 0.0001). There is also overlap, to extents greater
than expected by chance, with the clusters of SNPs whose
allele frequencies distinguish MNB African-American
polysubstance abusers from controls (p < 0.0001) [9], Jap-
anese methamphetamine abusers from controls (p <
0.0001) [11], Taiwanese methamphetamine abusers from
controls (p < 0.0007) [11] and more-frequently nicotine
dependent smokers of European ancestry from less-fre-
quently nicotine dependent smokers (p < 0.0001) [10].
We would anticipate the observed, highly-significant clus-
tering of SNPs that display nominally-positive results if
many of these reproducibly-positive SNPs lay near and
were in linkage disequilibrium with functional allelic var-
iants that distinguished substance-dependent subjects
from control subjects. We would not anticipate this degree
of clustering if the results were solely due to chance. The
Monte Carlo p values noted here are thus likely to receive
contributions from both the extent of linkage disequilib-
rium among the clustered, nominally-positive SNPs and
the extent of linkage disequilibrium between these SNPs
and the functional haplotype(s) that lead to the associa-
tion with substance dependence.
Neither controls for occult stratification nor for assay var-
iability appear to provide convincing alternative explana-
tions for most of the data obtained here. When we
examined the overlap between the 7620 clustered positive
SNPs from the ECA samples and: 1) the 2.5% of the SNPs
for which the noise in validating studies was highest and
2) the 2.5% of SNPs that displayed the largest differences
between Baltimore African-American vs European Ameri-
can control individuals, we found 15 and 245, respec-
tively, vs 185 expected by chance in each case.
We evaluated evidence for preferential brain and brain
regional expression of the 172 genes identified in Table 1
(body and legend). Brain libraries represented in dbEST
contained ESTs that corresponded to 91% (157/172) of
these genes. Expression for this set of genes (compared to allBMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
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genes) displayed nominal significance in thalamus (p <
10-8), amygdale (p = 5.6 × 10-9), hippocampus (p = 2.6 ×
10-5), frontal cortex (p = 0.015) and medulla (p = 0.039)
using hypergeometric tests (p values were Bonferroni cor-
rected for repeated comparisons). Assessments of the
"more reliable" subset of ESTs revealed significant overex-
pression in whole brain (p = 2.1 × 10-7), amygdala (p = 4.4
× 10-6), hippocampus (p = 0.0011), cerebellum (p =
0.0052), thalamus (p = 0.037) and cortex (p = 0.049) (p-
values were Bonferroni corrected).
Discussion
The current results 1) provide independent support for
GWA results from larger samples of research volunteers
studied for substance dependence phenotypes and 2) pro-
vide a control for one of the potential confounding fea-
tures of this previously-studied sample. The possibility
that genetic results from members of any sample of
research volunteers might not represent the genetics of
members of the general population is ever present. In
molecular genetic studies of substance dependence, how-
ever, features that are both 1) heritable and 2) differen-
tially present in substance dependent individuals might, a
priori, be considered to be especially likely to provide con-
founding influences. Cognitive abilities are highly herita-
ble. Cognitive tests in a number of samples of substance
dependent individuals have indicated differences in per-
formance (reviewed in [13]). A study in twin pairs whose
members were discordant for substance use concluded
that most of these cognitive differences were likely to be
heritable antecedents to, not just consequences of, the use
of addictive substances [37]. Cognitive abilities have been
Substantial overlaps of the zip codes in which subjects reported their residences Figure 1
Substantial overlaps of the zip codes in which subjects reported their residences. Fractional distributions (X axis) of 
zip codes (Y axis) in which ECA (solid blue bars) or MNB (dotted purple bars) subjects reported their residence. Areas from 
which NIDA and ECA recruitment efforts were dissimilar include 21214; Lauraville and surrounding areas and 21222, Dundalk 
and surrounding areas. Zip codes from which fewer than 3 individuals were recruited are not indicated.
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Table 1: Genes that contain overlapping clusters of nominally positive SNPs in both ECA and European-American MNB research 
volunteer samples that display nominal p < 0.05.
Clust SNPs
gene ch bp description ECA MNB p
A2BP1 16 6,009,133 ataxin 2-binding protein 1 16 42 0.0038
ACCN1 17 28,364,218 neuronal amiloride-sens cation chan 1 5 5 0.0240
ADARB2 10 1,218,073 RNA spec A deaminase B2 4 8 0.0420
ADCY2 5 7,449,345 adenylate cyclase 2 7 6 0.0210
AGBL4 1 48,822,129 ATP/GTP binding protein-like 4 3 8 0.0400
AK5 1 77,520,330 adenylate kinase 5 10 4 0.0090
AKAP6 14 31,868,274 A kinase anchoring protein 6 3 15 0.0210
ALK 2 29,269,144 anaplastic lymphoma kinase (Ki-1) 6 10 0.0470
ANKFN1 17 51,585,835 ankyrin-rep Fn III dom cont 1 3 14 0.0130
ATXN1 6 16,407,322 ataxin 1 3 17 0.0120
C18orf1 18 13,208,795 chromosome 18 open reading frame 1 4 6 0.0440
C3orf21 3 196,270,302 chromosome 3 open reading frame 21 4 4 0.0380
C8A 1 57,093,065 complement component 8 α polypep 3 7 0.0180
C9orf88 9 129,307,439 Chr 9 open reading frame 88 4 4 0.0220
CABIN1 22 22,737,765 calcineurin binding protein 1 4 4 0.0220
CACNA2D3 3 54,131,733 voltage det Ca chan α2/δ3 subunit 12 18 0.0091
CCBE1 18 55,252,124 collagen and calcium binding EGF domains 1 7 10 0.0090
CCDC63 12 109,769,194 coiled-coil domain containing 63 3 4 0.0290
CD180 5 66,513,872 CD180 molecule 5 5 0.0051
CDH13 16 81,218,079 cadherin 13 18 65 0.0019
CDH23 10 72,826,697 cadherin-like 23 7 4 0.0380
CGNL1 15 55,455,997 cingulin-like 1 3 11 0.0040
CHL1 3 213,650 close homolog of L1 3 12 0.0103
CHST11 12 103,370,614 chondroitin 4 sulfotransferase 11 4 4 0.0470
CIT 12 118,607,981 citron rho-interacting, serine/threonine kinase 21 5 6 0.0160
CNTN5 11 98,397,081 contactin 5 11 10 0.0390
CNTNAP2 7 145,444,386 contactin associated protein-like 2 22 9 0.0380
CPVL 7 29,001,772 carboxypeptidase vitellogenic-like 4 4 0.0290
CRYL1 13 19,875,810 crystalline λ1 4 5 0.0170
CSMD1 8 2,782,789 CUB and Sushi multiple domains 1 29 137 0.0014
CUGBP2 10 11,087,290 CUG triplet repeat RNA bind prot 2 16 4 0.0031
DAB1 1 57,236,167 disabled homolog 1 4 24 0.0140
DLC1 8 12,985,243 deleted in liver cancer 1 13 9 0.0059
DNAPTP6 2 200,879,041 DNA polymerase-transactivated protein 6 8 4 0.0140
DOCK2 5 168,996,871 dedicator of cytokinesis 2 3 7 0.0490
DPP6 7 154,060,464 dipeptidyl-peptidase 6 6 4 0.0250
EDNRA 4 148,621,575 endothelin receptor type A 3 4 0.0280
EFCAB4B 12 3,627,370 EF-hand calcium binding domain 4B 3 6 0.0165
EPHB1 3 135,996,950 EPH receptor B1 13 5 0.0090
ESRRG 1 214,743,211 estrogen-related receptor γ 3 14 0.0210
EVI1 3 170,285,244 ecotropic viral integration site 1 3 12 0.0047
F5 1 167,750,033 coagulation factor V 4 11 0.0049
FAM13A1 4 89,866,129 family with seq sim 13 A1 6 4 0.0360
FAM3C 7 120,776,141 family with sequence similarity 3 C 6 4 0.0109
FAM3D 3 58,594,710 family with sequence similarity 3 D 7 4 0.0063
FBXL17 5 107,223,348 F-box and leucine-rich repeat protein 17 6 6 0.0430
FGD2 6 37,081,401 FYVE, RhoGEF PH dom cont 2 3 4 0.0320
FHIT 3 59,710,076 fragile histidine triad gene 24 62 0.0030
FLJ11151 16 12,664,438 hypothetical protein FLJ11151 4 4 0.0380
FLJ32682 13 45,013,433 hypothetical protein FLJ32682 4 5 0.0180
FN1 2 215,933,422 fibronectin 1 3 5 0.0260
FOXP1 3 71,087,426 forkhead box P1 4 17 0.0180
FREM3 4 144,717,905 FRAS1 related extracellular matrix 3 4 6 0.0130
FRMD4A 10 13,725,718 FERM domain containing 4A 3 23 0.0090
GABBR2 9 100,090,187 GABA B receptor 2 11 6 0.0073
GLIS3 9 3,817,676 GLIS family zinc finger 3 13 18 0.0016
GRB10 7 50,625,259 growth factor receptor-bound protein 10 3 13 0.0083
GRID1 10 87,349,292 delta 1 inotropic glutamate rec 7 18 0.0130BMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
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GRIK1 21 29,831,125 kainate 1 inotropic glutamate rec 4 12 0.0150
GTF2F2L 4 148,646,691 general transcription fact IIFpolypep 2-L 3 3 0.0170
HPSE2 10 100,208,867 heparanase 2 6 18 0.0160
HS3ST4 16 25,611,240 heparan sulfate 3-O-sulfotransferase 4 4 11 0.0250
IMPA2 18 11,971,455 inositol(myo)-1(or 4)-monophosphatase 2 6 6 0.0064
IQGAP2 5 75,734,905 IQ motif cont GTPase activ prot 2 7 5 0.0170
JAKMIP1 4 6,106,385 janus kinase microtubule interacting protein 1 3 8 0.0138
KCNB1 20 47,421,912 Shab-rel volt-gated K chan 1 5 3 0.0190
KCNIP4 4 20,339,337 Kv channel interacting protein 4 13 9 0.0107
KCNJ6 21 37,918,655 inwardly-rect K chan J 6 3 8 0.0330
KCNMA1 10 78,299,366 large conduct Ca-act K chan M α1 8 8 0.0390
KIAA1576 16 76,379,984 KIAA1576 protein 3 6 0.0260
KREMEN1 22 27,799,106 kringle cont TM prot 1 5 4 0.0190
KSR2 12 116,389,387 kinase suppressor of ras 2 5 4 0.0430
LDLRAD3 11 35,922,188 low density lipoprotein recep cl A dom cont 3 3 6 0.0330
LTF 3 46,452,500 lactotransferrin 3 4 0.0290
MAGI1 3 65,314,946 membr-assoc G kinase WW PDZ dom cont 1 6 9 0.0380
MAGI2 7 77,484,310 membrane assoc G kinase WW PDZ dom 2 9 16 0.0430
MGC23985 5 147,252,464 similar to AVLV472 3 7 0.0085
MICAL2 11 12,088,714 calponin LIM cont microtub monoxygenase 2 8 8 0.0120
MTSS1 8 125,632,212 metastasis suppressor 1 9 9 0.0050
MTUS1 8 17,545,583 mitochondrial tumor suppressor 1 3 4 0.0090
MYO18B 22 24,468,120 myosin XVIIIB 15 8 0.0460
MYO3A 10 26,263,202 myosin IIIA 3 5 0.0018
NAALADL2 3 176,059,805 N-Ac α-linked acidic dipeptidase-L 2 4 5 0.0340
NFIA 1 61,320,881 nuclear factor I/A 4 4 0.0080
NLGN1 3 174,598,938 neuroligin 1 4 4 0.0260
OPCML 11 131,790,085 opioid binding protein/cell adhesion molecule-L 10 13 0.0076
PALM2 9 111,442,893 paralemmin 2 10 16 0.0220
PALM2-AKAP2 9 111,582,410 PALM2-AKAP2 protein 5 10 0.0021
PARD3B 2 205,118,761 par-3 partitioning defective 3 homolog B 3 5 0.0160
PDE4D 5 58,302,468 cAMP spec phosphodiesterase 4D 4 4 0.0140
PKD1L2 16 79,691,991 polycystic kidney disease 1-like 2 4 4 0.0060
PLD5 1 240,318,895 phospholipase D family 5 3 16 0.0300
PRKCA 17 61,729,388 protein kinase C α 6 4 0.0113
PRKCH 14 60,858,268 protein kinase C η 7 22 0.0300
PRKG1 10 52,504,299 cGMP dep protein kinase I 12 10 0.0014
PRPF4 9 115,077,795 PRP4 pre-mRNA process fact 4 homol 6 4 0.0360
PSD3 8 18,432,343 pleckstrin and Sec7 domain containing 3 8 16 0.0240
PTPN14 1 212,597,634 no rec prot Y phosphatase 14 10 4 0.0150
PTPRK 6 128,331,625 recept protein tyrosine phosphatase K 3 8 0.0062
PTPRT 20 40,134,806 recept prot Y phosphatase T 3 15 0.0190
RBMS3 3 29,297,947 sing strand RNA binding motif interact prot 5 13 0.0230
ROR2 9 93,524,705 receptor tyrosine kinase-L orphan recept 2 5 4 0.0290
RORA 15 58,576,755 RAR-related orphan receptor A 4 9 0.0220
SLC2A13 12 38,435,090 solute carrier family 2 13 4 4 0.0086
SLIT3 5 168,025,857 slit homolog 3 3 4 0.0370
SRGAP3 3 8,997,278 SLIT-ROBO Rho GTPase activating protein 3 4 23 0.0087
STK32B 4 5,104,428 serine threonine kinase 32B 3 25 0.0011
STK39 2 168,518,777 serine threonine kinase 39 4 4 0.0036
SYNE1 6 152,484,516 spectrin rep cont nuclear envelope 1 7 5 0.0034
TACC2 10 123,738,679 transforming acidic coil-coil cont prot 2 3 9 0.0430
TBC1D22A 22 45,537,213 TBC1 domain family 22A 3 8 0.0270
TEK 9 27,099,286 TEK tyrosine kinase, endothelial 3 9 0.0420
TG 8 133,948,387 thyroglobulin 4 4 0.0180
THSD4 15 69,220,842 thrombospondin I dom cont 4 3 11 0.0063
TMEM132C 12 127,318,855 transmembrane protein 132C 5 13 0.0084
TMEM132D 12 128,122,224 transmembrane protein 132D 8 11 0.0090
TMEM16D 12 99,712,716 transmembrane protein 16D 11 11 0.0320
TMTC1 12 29,545,024 transmemb tetratricopep rep cont 1 3 3 0.0035
TRPC4 13 37,108,795 transient receptor potential cation channel C 4 8 4 0.0140
TULP4 6 158,653,680 tubby like protein 4 6 9 0.0076
UNC5C 4 96,308,712 unc-5 homolog C 9 4 0.0162
Table 1: Genes that contain overlapping clusters of nominally positive SNPs in both ECA and European-American MNB research 
volunteer samples that display nominal p < 0.05. (Continued)BMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
Page 8 of 10
(page number not for citation purposes)
VAMP4 1 169,938,783 vesicle-associated membrane protein 4 3 5 0.0170
VAPB 20 56,397,651 vesicle-assoc memb protein-assoc prot B C 4 11 0.0034
VIT 2 36,777,418 Vitrin 3 9 0.0110
ZNF365 10 63,803,957 zinc finger protein 365 6 4 0.0340
ZNF406 8 135,559,213 zinc finger protein 406 16 4 0.0014
The numbers of nominally-positive SNPs that lay in clusters within the gene's exons and in 10 kb genomic flanking regions are noted for each 
sample. Chromosome number and initial chromosomal position for the cluster (bp, NCBI Mapviewer Build 36.1) are listed. Nominal p values for 
each gene are based on 10,000 Monte Carlo simulation trials. For each trial, the number of times randomly-selected segments of the genome that 
lie within genes are assessed for the same features displayed by the actual gene identified. Note that the very highly significant p values for the 
overall convergence noted between these two datasets (text) does account for multiple comparisons, while the much more modest p values for 
many of the individual genes (displayed here) do not. Genes that are identified by clustered nominally positive SNPs in both samples but whose 
gene-wise p values lie > 0.05 (perhaps, in part, due to the large size of the genes) include: C4orf13, PRKCE, UNC13C, KIAA1303, MYR8, DNAH11, 
ONECUT2, TGFBR3, TPD52L1, C9orf28, TMEM108, GALNT14, HECW2, NFIB, STS-1, KIAA1217, RAB3C, SNTG1, CPNE4, PTPRM, SLC39A11, 
MDS1, GPC5, ZNF533, NR5A2, RYR3, C8orf68, CTNNA2, GRM5, ATRNL1, ARL15, BTBD9, CNTNAP5, GALNTL4, PELI2, SNRPN, GPR98, 
ERC2, NFATC2, FLJ16124, GRM7, SORCS2, NPAS3, PARVB, IGL@ and LRP1B.
Table 1: Genes that contain overlapping clusters of nominally positive SNPs in both ECA and European-American MNB research 
volunteer samples that display nominal p < 0.05. (Continued)
shown to interact with willingness to volunteer for and/or
participate in research protocols in a number of settings
[1,12,14-25]. A number of personality features are also
highly heritable [38]. Neuroticism is both one of the more
heritable personality features and also the personality fea-
ture that has been demonstrated to be elevated in several
samples of substance dependent individuals [38]. Person-
ality features have also been linked to willingness to vol-
unteer for participation in research protocols [1,12,14-
25]. A number of psychiatric disorders that might also be
linked to differential willingness (or ability) to participate
as a research volunteer are also heritable and co-occur
with substance dependences at rates much greater than
chance [13].
It is also important to keep a number of limitations in
mind in considering the present results. 1) The pre-
planned approach used here demands that multiple nom-
inally-positive SNPs from each sample tag the same
genomic region that lies within a gene. Requirements that
nominally positive SNPs from the current dataset come
from each of the two 500 k array types add a technical
control. Monte Carlo approaches that do not require spec-
ification of underlying distributions can readily judge the
degree to which all of the observations made here could
be due to chance. Nevertheless, there have been no unan-
imous criteria for declaring "replication" or "conver-
gence" for GWA studies, a consideration worth
considering in evaluating the current results. 2) The ECA
samples are of modest size, limited by the numbers of
substance abusing or dependent individuals in the aging
Baltimore ECA cohort follow-up samples. Power calcula-
tions that document the modest power in European-
Americans samples revealed even more modest power for
the smaller number of African-American substance
dependent individuals in this sample; we have thus not
analyzed these samples. Modest power limits interpreta-
tion of negative data, substantially restricting inferences
about genes identified in the more robust dataset from
MNB research volunteers but not in these ECA samples. 3)
There is very highly significant confidence in the overall
set of convergent positive results reported here. However,
the values for each gene, tested individually, provide
much more modest levels of statistical assurance. 4) Focus
on data from autosomes here allows us to combine data
from male and female subjects, but misses potentially
important contributions from sex chromosomes. 5) The
individuals in the Baltimore ECA cohort were not initially
sampled based on their willingness to be volunteers.
However, participants needed to consent in order to be
able to be followed and studied genetically. Although the
overwhelming majority of the European-American partic-
ipants who were followed did consent to participation in
genetic studies, potential contributions that the non-con-
senting individuals might have made to the present results
remain unknown. 6) The pooling approach that we use
here provides excellent correlations between individually-
genotyped and pooled allele frequency assessments in val-
idation experiments. This approach has allowed us to use
these samples without adding additional confidentiality
burdens to these intensively-studied individuals. Never-
theless, estimates of allele frequencies based on pooled
data represent approximations of "true" allele frequency
differences that might be determined by error free individ-
ual genotyping of each participant. 7) There is no indica-
tion that the overall positive results reported here are
based on the SNPs whose assays provide more noise, and
no indication that occult stratification on racial/ethnic
lines contributed overall to the results that we obtain here.
However, we cannot totally exclude contributions of
occult stratification that cannot be detected by these over-
all screens to findings in specific genes. 8) The convergent
data derived from studies of individuals with dependence
on substances in several different pharmacological classes
supports the idea that many allelic variants enhance vul-
nerability to dependence on a number of substances.
These results do not exclude additional contributions
from genomic variants that influence vulnerability to spe-BMC Medical Genetics 2008, 9:113 http://www.biomedcentral.com/1471-2350/9/113
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cific substances. 9) We focus on identification of genes.
Although associations away from annotated genes can
also provide interesting results, the genes that we identify
in the present work provide a number of interesting views
of substance dependence. These data reinforce our obser-
vations that many of these genes are likely to contribute to
brain differences that are reflected in the mnemonic
aspects of addiction, and that some of them also provide
tempting targets for antiaddiction therapeutics. We dis-
cuss these ideas in more detail elsewhere [12,13].
More of the genes identified here are represented among
cDNAs cloned from brain libraries than is the case for all
human genes. The results focus attention on expression in
hippocampus, which manifests interesting roles in mne-
monic processes and cerebral cortical connections that
may provide additional clues to the pathophysiology of
human substance dependence. Although detailed discus-
sion of each of these groups of genes is beyond the scope
of this report, it is interesting to note that about 15% of
the genes enumerated in Table 1 can be related to cell
adhesion mechanisms. This is a much larger fraction that
the fraction of all genes, about 2%, that are identified as
cell adhesion molecules in a recent bioinformatic
approach to comprehensively identifying cell adhesion
molecules [39], supporting overrepresentation of these
genes among addiction-associated genes.
A number of the genes identified in this work are also
identified in genome wide association and/or candidate
gene datasets for heritable disorders or phenotypes that
co-occur with addictions. As we discuss elsewhere,
dependence-vulnerability GWA results overlap at levels
greater than expected by chance with GWA studies of cog-
nitive abilities, personality features, frontal lobe brain vol-
umes and bipolar disorder [13].
Conclusion
The observations in the present dataset that the findings
from a population-based sample converge strongly with
those made in larger research volunteer samples are reas-
suring. They support the idea that many of the molecular
genetic findings that we and others have previously
reported are not due simply to the methods used for ascer-
tainment of "cases" and "controls" for our studies in
research volunteers. It is important to note that this over-
all conclusion does not exclude contributions for some of
these sampling issues to findings in particular genes. Nev-
ertheless, the findings presented here promise to add to
ongoing processes for comparing GWA datasets from
research volunteers to those from population based sam-
ples. For dependence on alcohol, tobacco and other
drugs, as for many complex disorders, such data provides
an increasingly rich basis for improved understanding and
for personalization of prevention and treatment strate-
gies.
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